SynderBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SynderBio is a private, pre-revenue biotech firm founded in 2019, focusing on a proprietary cell separation platform. Its core technology addresses critical sample preparation bottlenecks in genomic sequencing, particularly for complex samples like tumors and immune cells. The company's initial market focus is on oncology and immunology research and diagnostics, with the potential to expand into various life science tools and services. As an early-stage platform company, its success hinges on commercial adoption, partnership development, and demonstrating clear advantages over existing sample preparation methods.

OncologyImmunology

Technology Platform

Patented cell separation technology designed to isolate specific cell types from complex biological samples with high purity, yield, and viability for genomic sequencing applications.

Opportunities

The rapid growth of single-cell analysis and liquid biopsy markets presents a large addressable opportunity for a superior sample preparation technology.

Forming strategic partnerships with large life science tools companies or diagnostic labs could accelerate commercialization and provide crucial validation.

Expanding the platform's utility beyond oncology into immunology, neuroscience, and infectious disease research could multiply its market potential.

Risk Factors

Intense competition from established, well-capitalized companies in the cell separation and sample prep market poses a significant commercial threat.

The company's pre-revenue status and reliance on external funding create financial vulnerability if development milestones are delayed.

Technology risk remains high if the platform fails to demonstrate clear, reproducible advantages over existing methods in independent hands.

Competitive Landscape

SynderBio competes in the life science tools and sample preparation market, facing direct competition from companies offering FACS systems (e.g., BD Biosciences, Beckman Coulter), MACS products (Miltenyi Biotec), and microfluidic-based cell sorting technologies (e.g., 10x Genomics, Berkeley Lights). Its success depends on differentiating through superior performance, ease of use, cost-effectiveness, or compatibility with high-demand workflows like single-cell sequencing.

More companies in Diagnostics & Precision Medicine →More companies in United States →